Menopause and treatments

Quality of Life Research

Volumn 9, Issue 1, 2000, Pages 695-707

  Ringa, V ^a  

^a INSERM   (France)

Author keywords

Benefits; Hormones; Menopause; Risks; Treatments

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; ESTROGEN THERAPY; FEMALE; FRACTURE; HUMAN; MENOPAUSE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034471090     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1008913605129     Document Type: Article

References (108)

1. The demography of menopause
2. What determines the age at the menopause?
3. Menarche, pregnancy, birth spacing and menopause among the Agta women foragers of Cagayan province, Luzon, the Philippines
4. Climacteric symptoms: A study in the Indian context
5. The age and symptomatology of natural menopause among United Arab Emirates women
6. Epidemiology of the menopause
7. Cigarette smoking and the age at menopause
8. The menopause
9. Menopause, mood and hormone replacement therapy: Methodological issues
10. Prevalence of climacteric complaints in a representative sample of middle age in Oslo, Norway
11. Defining menopause status: The impact of longitudinal data
12. Menopausal status: Subjectively and objectively defined
13. Menopause without symptoms: The endocrinology of menopause among rural Mayan Indians
14. Contested meanings of the menopause
15. Menopausal symptoms and symptom clustering in Chinese women
16. Characteristics of menopausal women seeking assistance
17. La ménopause. De l'Áge critique á la critique de l' áge
18. The south-east England longitudinal study of the climacteric and postmenopause
19. Pathogenesis of climacteric complaints: Ready for the change?
20. Causality, menopause and depression: A critical review of the literature
21. Osteoporosis and osteopenia
22. Epidemiology of osteoporosis and osteoporotic fractures
23. Involutional osteoporosis
24. Evidence of estrogen receptors in normal human osteoblast-like cells
25. The relative contributions of age and years since menopause to postmenopausal bone loss
26. Coronary heart disease in women, randomized clinical trials. HERS and RUTH
27. Menopause and risk of cardiovascular disease: The Framingham study
28. Menopause and the risk of coronary heart disease in women
29. Factor VII activation and menopausal status
30. Hormone replacement therapy: The perspectives for the 21st century
31. Breast cancer
32. Putting the risk of breast cancer in perspective
33. Prediction of bone density From vitamin D receptor alleles
34. Genetic studies of osteoporosis: What have we learned?
35. Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals
36. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: Randomised dose response study
37. Effects of estrogen or estrogen progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial
38. Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins
39. Various actions of oestrogens on the vascular system
40. Hormone replacement therapy - With or without added progestin - And which progestin?
41. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: A double-blind placebo-controlled study
42. Quality of life alter the menopause: Influence of hormonal replacement therapy
43. A quality of life perspective on who benefits from estradiol replacement therapy
44. Meta-analysis of estrogen therapy in the management of orogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee
45. Hormone replacement therapy
46. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal estrogen/progestin interventions (PEPI) trial
47. Hormone replacement therapy
48. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis
49. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
50. The heart and estrogen/progestin replacement study (HERS)
51. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women
52. Postmenopausal estrogen and prevention bias
53. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
54. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: Prospective cohort study in Gothenburg, Sweden
55. Trends in the use of hormone replacement therapy in eastern France between 1986 and 1993
56. Twelve-year trends in cardiovascular disease risk factors in the Minnesota Heart Survey. Are socioeconomic differences widening?
57. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
58. Hormone replacement therapy and Alzheimer's disease
59. Postmenopausal hormone use and risk for colorectal cancer and adenoma
60. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women
61. Hormone replacement therapy, reproductive history, and colon cancer: A multicenter, case-control study in the United States
62. Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA)
63. Postmenopausal hormone use and risk of large-bowel cancer
64. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
65. Hormone replacement therapy and colon cancer among members of a health maintenance organization
66. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
67. Case-control study of venous thromboembolism risk in users of hormone replacement therapy
68. Prospective study of exogenous hormones and risk of pulmonary embolism in women
69. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
70. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
71. Hormone replacement and cancer
72. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
73. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
74. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
75. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
76. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
77. Design of the Women's Health Initiative clinical trial and observational study
78. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis
79. Compliance with hormone therapy
80. Compliance with hormonal replacement therapy
81. Duration of hormonal replacement therapy in general practice: A follow-up study
82. Hormone substitution therapy. Side-effects and compliance of various therapeutic regimens
83. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy
84. Utilisation of hormone replacement therapy by women doctors
85. Compliance with long-term oral hormonal replacement therapy
86. The effect of postmenopausal estrogen therapy on bone density in elderly women
87. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women
88. Womens attitudes and knowledge about the climacteric period and its treatment. A Swedish population-based study
89. Estrogen replacement therapy and fractures in older women
90. Treatment of osteoporosis in elderly women
91. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
92. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
93. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
94. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
95. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
96. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
97. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
98. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)
99. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year. double-blind, placebo-controlled study
100. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
101. A tale of two worlds in prescribing etidronate for osteoporosis
102. Prevention of nonvertebral fractures by alendronate. A meta-analysis
103. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
104. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
105. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
106. Tibolone: A review
107. The social and cultural context of menopause